Medical/Pharmaceuticals

Akeso Enrolled First Patient in The Phase III Clinical Trial of Ivonescimab in Combination with Chemotherapy for First-Line Treatment of Triple-Negative Breast Cancer

HONG KONG, Feb. 20, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced the company has successfully enrolled the first patient in its multicenter, randomized, double-blind Phase III clinical trial of ivonescimab in combination with chemotherapy for first-line tr...

2025-02-21 08:47 2465

Bestqool Unveils Four-Wavelength Pro Series and Second-Gen Mobile Stand at Original Price

NEW YORK, Feb. 20, 2025 /PRNewswire/ -- In a recent announcement, Bestqool is upgrading both the Pro100 and Pro200 to the four-wavelength configuration (630 nm, 660 nm, 850 nm, 940 nm) as the Pro 300

2025-02-21 01:09 2589

FIRST AND ONLY TREATMENT FOR CHRONIC HYPOPARATHYROIDISM APPROVED IN AUSTRALIA

* YORVIPATH® (palopegteriparatide) is now registered by the Therapeutic Goods Administration (TGA) for the treatment of chronic hypoparathyroidism in adults1 * First-in-class novel PTH replacement therapy * Australia becomes the first country to obtain Marketing Authorisation for YORVIPATH s...

2025-02-21 00:01 2812

NAVER D2SF-Backed PranaQ® Receives FDA 510(k) Clearance for TipTraQ, an AI-Enabled Home Sleep Apnea Test

SEOUL, South Korea, Feb. 20, 2025 /PRNewswire/ -- PranaQ, backed by NAVER D2SF continues to push the boundaries of AI-powered healthcare solutions. NAVER D2SF, NAVER's corporate venturing arm, actively collaborates with startups to drive innovation and sustainable growth. This investment undersco...

2025-02-21 00:00 2664

111 to Announce Fourth Quarter and Fiscal Year 2024 Unaudited Financial Results on March 20, 2025 - Conference Call to Follow

SHANGHAI, Feb. 20, 2025 /PRNewswire/ -- 111, Inc. (NASDAQ: YI) ("111" or the "Company"), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream inChina, today announced that it will repor...

2025-02-20 18:00 2424

Hong Kong Pharma Digital Technology Holdings Limited Partners with Leading Chinese E-commerce Platform to Enhance Cross-Border Logistics Services

NEW YORK, Feb. 20, 2025 /PRNewswire/ -- Hong Kong Pharma Digital Technology Holdings Limited has recently signed a cooperation agreement with a leading technology-driven e-commerce platform serving hundreds of millions of consumers. This partnership aims to revolutionize cross-border logistics s...

2025-02-20 17:23 2225

Harbour BioMed and Insilico Medicine Achieve Strategic Collaboration to Advance AI-Driven Antibody Discovery and Development

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Feb. 20, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immunology and oncology, a...

2025-02-20 15:31 2509

Nona Biosciences Announces Licensing Agreement with the University of Alabama at Birmingham to Support B Cell Development Research

CAMBRIDGE, Mass., Feb. 19, 2025 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing a total solution from "Idea to IND" (I to I™), today announced a licensing agreement with theUniversity of Alabama at Birmingham (UAB) to support their research in B cell development. Und...

2025-02-20 09:21 2225

Clarity receives US FDA Fast Track Designation for the treatment of metastatic castration-resistant prostate cancer patients with Cu-67 SAR-bisPSMA

SYDNEY, Feb. 19, 2025 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce thatthe Un...

2025-02-19 22:09 2805

Brexogen and BMI Korea Enter Strategic Technology Transfer Agreement for Exosome Therapeutics

Out-licenses BxC-I17e, Exosome-Based Therapeutics for New Indications KRW 3 Billion Non-Refundable Upfront Payment + Milestone Payments + Double-Digit Percentage Royalties SEOUL, South Korea, Feb. 19, 2025 /PRNewswire/ -- Brexogen , a leading biotechnology company special...

2025-02-19 21:00 2113

Biosion, Inc. Appoints Kedan Lin, Ph.D., as Chief Development Officer and President of Biosion US

NEWARK, Del. and NANJING, China, Feb. 19, 2025 /PRNewswire/ -- Biosion, Inc. ("Biosion"), a global clinical-stage biotechnology company, is pleased to announce the appointment ofKedan Lin, Ph.D., as Chief Development Officer and President of Biosion US. With over two decades of expertise in biote...

2025-02-19 19:39 1951

AESOP Technology Unveils World's First Machine Learning Model to Combat Wrong-Site Surgery

SAN FRANCISCO, Feb. 18, 2025 /PRNewswire/ -- Wrong-site surgery (WSS), a critical "Never Event," represents a failure that should never occur in healthcare. Yet, due to underreporting, the true prevalence of these incidents remains obscured, jeopardizing patient safety and healthcare management.A...

2025-02-19 00:30 2123

VIVOZON Pharmaceutical Obtains MFDS Approval for UNAFRA Inj.: A Breakthrough Non-Opioid analgesic

SEOUL, South Korea, Feb. 18, 2025 /PRNewswire/ -- On February 17, VIVOZON Pharmaceutical announced that its non-opioid analgesic, UNAFRA Inj., was approved onDecember 12, 2024. (active ingredient: Opiranserin HCl), has received approval from the Ministry of Food and Drug Safety (MFDS). With this ...

2025-02-18 23:35 1922

HIMIAO Unveils BhairCx3™ Shine Factor ---- A Breakthrough in Feline Fur Care

XI'AN, China, Feb. 18, 2025 /PRNewswire/ -- The number of cat owners has surged dramatically in recent years. According to the 2025 White Paper onChina's Pet Industry, the number of pet cats inChina surpassed 71.53 million in 2024, accounting for 57.6% of all pet-owning households. However, as ca...

2025-02-18 22:15 1938

Transformation and rapid development of Visionary through the business integration

TORONTO, Feb. 18, 2025 /PRNewswire/ -- On January 26, 2025, Visionary's 2024 Annual Conference was held inToronto, celebrating the successful listing of Visionary's Pegasus New Energy Vehicles, SBS Green Energy, UBX FinTech, and American Precision Biotech on the U.S. OTC market. 2024 is a year of...

2025-02-18 22:00 2882

AHG Utilizes DeepSeek to Advance AI in Healthcare

QINGDAO, China, Feb. 18, 2025 /PRNewswire/ -- Akso Health Group (NASDAQ: AHG) (hereinafter referred to as "Akso Health," "the Company," or "we") announced today its integration of DeepSeek's advanced artificial intelligence technology. This initiative aims to further enhance AI-powered medical c...

2025-02-18 21:30 2269

Fangzhou Inc. integrates DeepSeek open-source AI Model to enhance Internet healthcare

SHANGHAI, Feb. 18, 2025 /PRNewswire/ -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in Internet healthcare solutions, announced the successful integration and local deployment of the DeepSeek-R1 open-source large language model onFebruary 8th. This upgrade is expected to yiel...

2025-02-18 21:16 2253

PharmaBlock Launches Commercial GMP Workshop 503 at Zhejiang Site

NANJING, China, Feb. 18, 2025 /PRNewswire/ -- PharmaBlock Sciences (Nanjing), Inc. (Stock code: 300725.SZSE) has announced the official launch of its commercial GMP Workshop 503 (W503) at PharmaBlock Zhejiang. The new workshop significantly enhances production capacity and further refines the hi...

2025-02-18 19:52 2198

WuXi Biologics Awarded Platinum Medal by EcoVadis Sustainability Rating for Second Consecutive Year

* Ranked among the top 1% of more than 150,000 companies across 185 countries * Trusted by global partners for strong sustainability commitment * Recognized as a leader in Green CRDMO, driving innovation for a healthier future SHANGHAI, Feb. 18, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio"...

2025-02-18 17:00 2747

CJ Bioscience to Present Preclinical Data on Inflammatory Bowel Disease Pipeline Candidate CJRB-201 at 'ECCO 2025'; Clinical Entry Targeted for 2026

* 'CJRB-201', a proprietary strain of Faecalibacterium with potent its anti-inflammatory effects, has demonstrated the strongest induction of regulatory T cells (Tregs) among analyzed strains. * Preclinical studies in multiple animal models confirm significant improvements in key disease indi...

2025-02-18 15:00 2410
1 ... 51525354555657 ... 251

Week's Top Stories